Tredje AP fonden boosted its position in Humana Inc (NYSE:HUM) by 6.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,855 shares of the insurance provider’s stock after purchasing an additional 699 shares during the quarter. Tredje AP fonden’s holdings in Humana were worth $3,985,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Evoke Wealth LLC purchased a new stake in Humana in the 3rd quarter worth approximately $26,000. Quest Capital Management Inc. ADV bought a new position in shares of Humana in the 3rd quarter worth $30,000. Penserra Capital Management LLC bought a new position in shares of Humana in the 3rd quarter worth $31,000. Lighthouse Financial Advisors Inc. bought a new position in shares of Humana in the 4th quarter worth $31,000. Finally, Psagot Investment House Ltd. bought a new position in shares of Humana in the 3rd quarter worth $35,000. Institutional investors and hedge funds own 75.72% of the company’s stock.
In related news, Director James J. /Ky Obrien sold 2,500 shares of Humana stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $345.21, for a total transaction of $863,025.00. Also, insider Elizabeth D. Bierbower sold 5,347 shares of Humana stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $370.00, for a total transaction of $1,978,390.00. Following the transaction, the insider now directly owns 23,439 shares of the company’s stock, valued at $8,672,430. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 45,294 shares of company stock valued at $15,894,412. Corporate insiders own 0.54% of the company’s stock.
HUM has been the topic of a number of research analyst reports. Wells Fargo & Co reissued an “overweight” rating and issued a $400.00 price target (up previously from $338.00) on shares of Humana in a report on Wednesday, December 11th. Credit Suisse Group increased their target price on shares of Humana from $378.00 to $400.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. JPMorgan Chase & Co. increased their target price on shares of Humana from $437.00 to $448.00 and gave the company an “overweight” rating in a report on Friday, January 3rd. Cantor Fitzgerald increased their target price on shares of Humana from $345.00 to $400.00 and gave the company an “overweight” rating in a report on Wednesday, February 5th. Finally, Barclays increased their target price on shares of Humana from $327.00 to $358.00 and gave the company an “overweight” rating in a report on Friday, December 6th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $384.00.
Humana stock traded down $14.96 during trading hours on Tuesday, reaching $331.20. The stock had a trading volume of 92,230 shares, compared to its average volume of 1,063,178. The stock has a market cap of $48.84 billion, a PE ratio of 16.56, a PEG ratio of 1.48 and a beta of 0.96. Humana Inc has a 52 week low of $225.65 and a 52 week high of $384.99. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.82 and a quick ratio of 1.82. The company has a fifty day simple moving average of $361.43 and a 200-day simple moving average of $320.37.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 5th. The insurance provider reported $2.28 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.20 by $0.08. Humana had a net margin of 4.17% and a return on equity of 20.89%. The firm had revenue of $16.30 billion during the quarter, compared to analysts’ expectations of $16.15 billion. During the same period last year, the company posted $2.65 EPS. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. Research analysts predict that Humana Inc will post 18.64 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Tuesday, March 31st will be given a $0.625 dividend. This represents a $2.50 annualized dividend and a dividend yield of 0.75%. This is a boost from Humana’s previous quarterly dividend of $0.55. The ex-dividend date is Monday, March 30th. Humana’s dividend payout ratio (DPR) is currently 12.31%.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More: Why does a company issue an IPO?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.